Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Gains from Sales and Divestitures: 2018-2020

Historic Gains from Sales and Divestitures for UNITED THERAPEUTICS (UTHR) over the last 2 years, with Mar 2020 value amounting to $104,818.

  • UNITED THERAPEUTICS's Gains from Sales and Divestitures rose 127.73% to $104,818 in Q1 2020 from the same period last year, while for Mar 2020 it was $104,818, marking a year-over-year increase of 127.73%. This contributed to the annual value of $74,324 for FY2019, which is 290.13% up from last year.
  • According to the latest figures from Q1 2020, UNITED THERAPEUTICS's Gains from Sales and Divestitures is $104,818, which was up 41.03% from $74,324 recorded in Q4 2019.
  • UNITED THERAPEUTICS's 5-year Gains from Sales and Divestitures high stood at $104,818 for Q1 2020, and its period low was $17,820 during Q2 2018.
  • Over the past 3 years, UNITED THERAPEUTICS's median Gains from Sales and Divestitures value was $55,192 (recorded in 2019), while the average stood at $51,762.
  • Data for UNITED THERAPEUTICS's Gains from Sales and Divestitures shows a peak YoY skyrocketed of 290.13% (in 2019) over the last 5 years.
  • UNITED THERAPEUTICS's Gains from Sales and Divestitures (Quarterly) stood at $19,051 in 2018, then soared by 290.13% to $74,324 in 2019, then surged by 127.73% to $104,818 in 2020.
  • Its Gains from Sales and Divestitures stands at $104,818 for Q1 2020, versus $74,324 for Q4 2019 and $69,761 for Q3 2019.